GSK plc (GSK) is held by 9 of 149 tracked super-investor funds (144 filed in Q2) in 2026 Q2 13F filings, with 2 funds adding and 7 funds trimming or exiting versus the previous quarter. Latest close $48.58 as of Nov 18, 2026.
Data as of Nov 18, 2026 (prices) · 2026 Q2 13F filings (quarter ended Jun 30, 2026) · Latest Form 4: none in the last 90 days · Congress to Nov 16, 2026.
Mondrian Investment Partners · Hillman Capital Management · Dodge & Cox Funds — 9 tracked funds hold GSK. See all holders.
No insider open-market activity or Congress trades reported for this stock in the recent window. Insider trading · Politician trading.
Arcos Dorados Holdings Inc. (ARCO) · DuPont de Nemours, Inc. (DD) · KT CORP (KT) · KONINKLIJKE PHILIPS NV (PHG) · SHINHAN FINANCIAL GROUP CO LTD (SHG) — stocks the same funds also hold. See all related stocks.
| Fund | Portfolio weight | Shares | Change vs prev. quarter |
|---|---|---|---|
| Mondrian Investment Partners | 3.97% | 4,910,830 | TRIMMED (-1.5%) Q3 filed Oct 23 |
| Hillman Capital Management | 3.51% | 92,383 | TRIMMED (-5.2%) Q3 filed Nov 16 |
| Dodge & Cox Funds | 1.32% | 48,197,514 | TRIMMED (-17.8%) Q3 filed Nov 13 |
| Kahn Brothers Group | 1.31% | 158,438 | TRIMMED (-1.6%) Q3 filed Nov 16 |
| Tweedy Browne | 0.32% | 81,527 | TRIMMED (-0.3%) Q3 filed Nov 4 |
| Saturna Capital | 0.03% | 41,025 | ADDED (+23.0%) Q3 filed Nov 16 |
| Atalanta Sosnoff Capital | 0.01% | 6,144 | TRIMMED (-7.9%) Q3 filed Nov 10 |
| Pzena Investment Management | <0.01% | 24,507 | ADDED (+30.2%) Q3 filed Oct 30 |
| Causeway Capital Management | <0.01% | 7,163 | TRIMMED (-35.5%) Q3 filed Nov 13 |
Source: SEC Form 13F filings, quarter ended Jun 30, 2026. Change labels compare each fund’s 2026 Q2 filing with its previous filing. Fund counts aggregate every share class mapped to this ticker.
Price change since quarter-end: -4.0% from the close on the first trading day after the quarter ended (Jul 1, 2026) to the latest close (Nov 17, 2026). 13F does not report purchase prices — this is the price change since the quarter-end close, not a gain on any fund’s actual purchase.
Filing season: the Q3 2026 13F tracker follows every tracked fund’s filing for the quarter ended Sep 30, 2026, with its biggest buys and sells.
Closing prices (unadjusted for dividends), last 2 years — 501 trading days to Nov 18, 2026. Dashed lines mark 13F filing deadlines. Source: Yahoo Finance daily bars.
| Institutions holding | 1,041 of 8,857 filers |
| Long-only filers among them | 1,033 |
| Change vs 2026 Q1 | +12 net · 935 entered · 923 exited |
| Shares reported, all filers | 346,033,575 |
| Reported value, all filers | $17.1B |
Source: SEC Form 13F data sets — every filer's latest report for the quarter ended Jun 30, 2026, not just the tracked funds above; changes compare with the quarter ended Mar 31, 2026. Share counts and values are summed as reported in the filings (a small number of filers report values in thousands of dollars, so value totals are as-filed sums).
| Exchange | NYSE |
| Industry | Pharmaceutical Preparations (SIC 2834) |
| Revenue · FY2025 | 32.7B GBP |
| Net income · FY2025 | 6.3B GBP |
| Total assets · FY2025 | 61.1B GBP |
| Shares outstanding | 4,315,445,026 |
| Market cap (at latest close) | $209.6B |
Source: SEC EDGAR company filings (submissions and company facts), collected Oct 30, 2026. Shares outstanding as reported Dec 31, 2025.
| Shares short · Oct 15, 2026 | 14,579,567 |
| Share of shares outstanding | 0.34% |
| Days to cover | 2.14 |
Shares short at recent settlements — Jul 31, 2026: 14.5M · Aug 14, 2026: 14.8M · Aug 31, 2026: 13.5M · Sep 15, 2026: 14.7M · Sep 30, 2026: 14.8M · Oct 15, 2026: 14.6M.
Source: FINRA Equity Short Interest (biweekly settlement data). Shares outstanding from SEC filings as of Dec 31, 2025.
| Shares failed to deliver · Oct 14, 2026 | 0 |
| Share of shares outstanding | 0.00% |
| Fails as a share of short interest · Oct 15, 2026 | 0.0% |
Fails to deliver at recent settlements — Jul 31, 2026: 0 · Aug 14, 2026: 40K · Aug 31, 2026: 0 · Sep 15, 2026: 0 · Sep 30, 2026: 297 · Oct 14, 2026: 0.
Source: SEC Fails-to-Deliver data (semi-monthly files, published about two weeks after each settlement date). Each figure is the balance of shares not yet delivered on that date; a stock absent from that date’s file counts as zero. See our research on whether fails to deliver predict returns. Shares outstanding from SEC filings as of Dec 31, 2025.
Data unavailable — no Form 4 transactions for this ticker were parsed in the last 90 days.
| Filed | Seller | Role | Shares to sell | Market value | Approx. sale date | Source |
|---|---|---|---|---|---|---|
| Aug 20, 2026 | Martinez Maria E | Officer | 44,397 | $2.3M | Aug 20, 2026 | SEC filing |
A Form 144 notice is a planned sale, not a completed sale. Most recent first. Source: SEC Form 144 filings, 63,013 notices from Apr 13, 2023 to Oct 9, 2026.
| Filed | Filer | Form | Shares | % owned | Event date | Source |
|---|---|---|---|---|---|---|
| Aug 13, 2026 | Dodge & Cox | SC 13G/A | 173,259,068 | 4.3% | Jun 30, 2026 | SEC filing |
| May 6, 2026 | FMR LLC | SC 13G | 234,936,060.81 | 5.8% | Mar 31, 2026 | SEC filing |
| Mar 7, 2025 | BlackRock, Inc. | SC 13G/A | 369,576,114 | 8.9% | Dec 31, 2024 | SEC filing |
One filing is one row; a filing may list several reporters and the first is shown. Figures are as filed, including amendments that report zero shares after a transfer. Source: SEC Schedule 13D/G filings, 57,443 filings parsed to Oct 2, 2026.
Data unavailable — no congressional STOCK Act transactions for this ticker were parsed in the current window (as of Nov 16, 2026).
Industry: Pharmaceutical Preparations (SIC 2834). Standing committees with jurisdiction over this industry: Senate Committee on Health, Education, Labor, and Pensions, House Committee on Energy and Commerce.
None of the members who traded this stock in the current window sit on these committees.
Assignments are the current (119th Congress) rosters. A trade made in an earlier Congress may have been made under a different assignment. Jurisdiction is by industry (SEC SIC code), not by anything the company said or did. Same rule as our committee-jurisdiction study.
Lobbying: 106 Lobbying Disclosure Act filings named this company as client, 1999–2026; most common issues: Health Issues (106), Copyright/Patent/Trademark (99), Medicare/Medicaid (99).
Federal contracts: no obligated amounts found for this ticker (USASpending, fiscal years 2021–2026).
Lobbying filings are matched by company core name; a filing can match more than one ticker. Contract amounts are obligated amounts (money committed, not money spent), matched by recipient name — contracts under a subsidiary’s name can be missed. Sources: Senate Lobbying Disclosure Act filings; USAspending.gov. See Methodology.
This stock does not currently pass any tracked screen.
| 13F signal (2021 Q3 – 2026 Q1) | Events | Win rate | Avg return | SPY | Excess |
|---|---|---|---|---|---|
| Heavy accumulation — 3+ tracked funds increased together | 10 | 70.0% | +5.7% | +3.1% | +2.6% |
| Heavy exit — 3+ tracked funds sold out together | 1 | 100.0% | +11.2% | +4.4% | +6.9% |
Measured from SEC 13F filings: entry at the close on the first trading day after each quarter’s filing deadline, exit one quarter later on the same rule, dividend-adjusted closes. Past records do not guarantee future results — see Track Record and Methodology.
Also held by the tracked funds that hold GSK — ranked by lift, the co-holding pattern described in Methodology: Arcos Dorados Holdings Inc. (ARCO) · DuPont de Nemours, Inc. (DD) · KT CORP (KT) · KONINKLIJKE PHILIPS NV (PHG) · SHINHAN FINANCIAL GROUP CO LTD (SHG) · Sanofi (SNY) · NOVO NORDISK A S (NVO) · PNC FINANCIAL SERVICES GROUP, INC. (PNC).
No Form 8-K filings for this ticker in the index (Jan 2023 – present).
Arcos Dorados Holdings Inc. (ARCO) · Track Record: how the signals scored · Practice timing on GSK
One email a week: the week’s new filings and research. Subscribe free
Open the interactive tool →Live screens, charts and backtests for every tracked stock, fund and signal — free, no sign-up.